These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6547355)

  • 21. [Statistical tests for bioequivalence].
    Peil H; Häselbarth V
    Arzneimittelforschung; 1985; 35(10):1489-94. PubMed ID: 4074402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Testing of bioequivalence of a new sotalol hydrochloride preparation in comparison to a standard formulation].
    Herrmann R; Kleinbloesem CH
    Arzneimittelforschung; 1995 Aug; 45(8):849-52. PubMed ID: 7575745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On Bayesian methods for bioequivalence.
    Selwyn MR; Hall NR
    Biometrics; 1984 Dec; 40(4):1103-8. PubMed ID: 6398710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of absorption characteristics of microemulsion cyclosporine products over the last 2 years in Indian subjects.
    Singh S; Sharma DR
    J Indian Med Assoc; 1999 Jul; 97(7):292-3. PubMed ID: 10643196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The importance of selective analytical techniques in bioequivalence testing.
    Lapka R; Ulc I; Kakác B; Rejholec V
    Pharmazie; 1988 Jan; 43(1):50-1. PubMed ID: 3375307
    [No Abstract]   [Full Text] [Related]  

  • 27. Radioimmunological analysis of cyproterone acetate in human serum. Comparison with a gas chromatographic/mass spectrometric method and influence of each method on the outcome of a bioequivalence trial.
    Baumann A; Kulmann H; Gorkov V; Mahler M; Kuhnz W
    Arzneimittelforschung; 1996 Apr; 46(4):412-8. PubMed ID: 8740090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bioequivalence of a new tablet formulation of sotalol hydrochloride in comparison to a standard preparations].
    Herrmann R; Kleinbloesem CH
    Arzneimittelforschung; 1994 May; 44(5):589-92. PubMed ID: 8024627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma pooling to expedite bioequivalence estimation of rifampicin in fixed dose combinations.
    Panchagnula R; Parmar J; Kaur JK; Singh I; Bhade SR
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):161-7. PubMed ID: 16810342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bioequivalence studies of pharmaceutical preparations].
    Vetchý D; Frýbortová K; Rabisková M; Danecková H
    Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Introduction to the problems of clinical pharmacological research].
    Rahlfs VW
    Int J Clin Pharmacol; 1972 Nov; 6(4):385-90. PubMed ID: 4565837
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical trial of drugs (10): evaluation of drugs].
    Sjöqvist F
    Lakartidningen; 1970 Jun; 67():Suppl II:111+. PubMed ID: 4920747
    [No Abstract]   [Full Text] [Related]  

  • 35. [Bioequivalence of generic drugs: sense and nonsense].
    Brune K; Dietzel K
    Fortschr Med; 1988 Nov; 106(33):16-7. PubMed ID: 3209169
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative bioavailability of two brands of carbamazepine. Reply from the authors.
    Bhatt AD
    J Assoc Physicians India; 1989 Sep; 37(9):619-20. PubMed ID: 2698888
    [No Abstract]   [Full Text] [Related]  

  • 37. Bioequivalence assessment and the conduct of bioequivalence trials: a European point of view.
    Herchuelz A
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):149-52. PubMed ID: 8839688
    [No Abstract]   [Full Text] [Related]  

  • 38. Half-life revisited: implication in clinical trials and bioavailability/bioequivalence evaluation.
    Chen ML; Pelsor FR
    J Pharm Sci; 1991 Apr; 80(4):406-8. PubMed ID: 1865346
    [No Abstract]   [Full Text] [Related]  

  • 39. A comment on optimal allocations for bioequivalence studies.
    Senn S; Grieve AP
    Biometrics; 1999 Dec; 55(4):1314-5. PubMed ID: 11315090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "One-size-fits-all" in bioavailability and bioequivalence testing?
    Blume HH
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):419-20. PubMed ID: 19640347
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.